Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

A stable latent reservoir for HIV-1 in resting CD4+ T cells is the principal barrier to a cure,–.
Curative strategies that target the reservoir are being tested, and require accurate, scalable …

Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might
minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after …

Rare CD4 T cells that contain HIV under antiretroviral therapy represent an important barrier
to HIV cure,–, but the infeasibility of isolating and characterizing these cells in their natural …

HIV persists in a small pool of latently infected cells despite antiretroviral therapy (ART).
Identifying cellular markers expressed at the surface of these cells may lead to novel …

Despite antiretroviral therapy, HIV-1 persists in memory CD4+ T cells, creating a barrier to
cure. The majority of HIV-1 proviruses are defective and considered clinically irrelevant …

In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent
form where there is minimal transcription or protein expression. Latently infected cells are a …

The phenotypic characterization of the cells in which HIV persists during antiretroviral
therapy (ART) remains technically challenging. We developed a simple flow cytometry …

The mechanisms responsible for the persistence of HIV-1 after many years of suppressive
antiretroviral therapy (ART) have been only partially elucidated. Most of the studies …